Skip to main content

 Partners in Discovery

Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram Cancer Center is at the forefront of new discoveries that help us prevent, find, treat, manage and cure cancer. But we can't make these discoveries alone. Our patients, caregivers, community leaders, donors, volunteers, and educators contribute their insight, time, and passion to advancing the discoveries that lead us closer to a cure.

No matter how cancer has touched your life, you are a key partner in our efforts to save lives and improve the quality of life for those with cancer. 

Proven Track Record

A leader in research, innovation and treatment. We are one of 50 National Cancer Institute-designated Comprehensive Cancer Centers, dedicated to an integrated and patient-focused approach.

NCI badge

Patients, Partners, Progress

Our patients and families are our most important partners in discovery – and the motivation behind our efforts to advance research and improve cancer care.    

Read their stories from Momentum magazine. 

Cancer Center News

Latest news about our research, patient care programs, outreach and educational events.

Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Vanderbilt team shows how stomach bug can trigger cancer

Researchers have obtained the first high-resolution image of a molecular “machine” used by the insidious stomach bug Helicobacter pylori to inject a cancer-causing protein into the stomach lining.

Health disparity for blacks exists within lung screening guidelines

The U.S. Preventive Services Task Force (USPSTF) guidelines that determine which smokers qualify for CT scans exclude significant numbers of African Americans who develop lung cancer, according to a study from Vanderbilt researchers.

Biomarkers of DNA methylation can be a predictor of breast cancer risk

Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk, according to a study published in Journal of the National Cancer Institute.

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a recent multi-institutional study.

Potential probe for early ovarian cancer

Vanderbilt researchers have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme.

Expert Q&A: Understanding a new approach to cancer treatment

Precision oncology expert Dr. Ben Ho Park sheds light on cancer treatment innovations.